CD4 and neoplasm: However, further investigations are needed to define the antigen cross-reactivity of CD4+ CTL, to develop approaches that recruit pathogen-specific, cytotoxic CD4+ T cells into tumors with low immunogenicity and to unleash strong cytotoxic T cell responses against tumor cells in vivo without causing severe immune-related adverse events.